Tarsus Pharmaceuticals, Inc. (TARS) Tops Q3 EPS by 5c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q3 EPS of ($0.30), $0.05 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $118.7 million versus the consensus estimate of $114.22 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Intuit (INTU) PT Lowered to $370 at Freedom Broker
• Morgan Stanley on Ford (F): 'We remain bullish Ford Energy'
• Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip